Home › Companies › Theravance Biopharma, Inc. › 2025-2026

Theravance Biopharma, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Theravance Biopharma, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.

9Reported items
214Asset managers
1,853Fund votes
2026-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Theravance Biopharma, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Theravance Biopharma, Inc.

These tallies are Theravance Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Theravance Biopharma, Inc. — official shareholder meeting results, meeting held 2026-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Laurie Smaldone Alsup	42,725,649	124,187	53,867	--	4,156,175	Majority: yes
Elect Director: Susannah Gray	42,231,530	618,306	53,867	--	4,156,175	Majority: yes
Elect Director: Dean J. Mitchell	42,557,257	297,316	49,130	--	4,156,175	Majority: yes
Elect Director: Donal O'Connor	42,535,463	319,110	49,130	--	4,156,175	Majority: yes
Elect Director: Deepika R. Pakianathan	41,936,019	918,543	49,141	--	4,156,175	Majority: yes
Elect Director: Rick E Winningham	42,474,538	377,274	51,891	--	4,156,175	Majority: yes
Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:	42,631,324	221,196	51,183	--	4,156,175	Majority: yes

Source: Theravance Biopharma, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.

How asset managers voted at the Theravance Biopharma, Inc. 2025-2026 meeting

Each item below shows how the 214 asset managers that disclosed a Theravance Biopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Theravance Biopharma, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approve the non-binding advisory resolution regarding the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 42,631,324AGAINST: 221,196

Theravance Biopharma, Inc.’s own tally for this item (“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”): 42,631,324 for, 221,196 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 83% for, 0.5% against (83% of the company cast a for/against vote).

The 213 asset managers below cast 99.7% of the shares they voted on this item FOR (34,613,200 for, 99,669 against).

FOR 99.6%

FOR: 34,613,200 (99.7%)AGAINST: 99,669 (0.3%)ABSTAIN: 13,277 (0.0%)NOT VOTED: 1,214 (0.0%)

Largest asset managers voting on “Approve the non-binding advisory resolution regarding the compensation of our named executive officers.” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Madison Avenue Partners, LP	8,944,605	0	For
Newtyn Management, LLC	4,036,218	0	For
BlackRock	3,660,082	0	For
Irenic Capital Management LP	2,566,196	0	For
Vanguard	2,479,381	0	For
Fidelity	1,096,568	0	For
GEODE CAPITAL MANAGEMENT, LLC	965,125	0	For
Weiss Asset Management LP	765,611	0	For
Janus Henderson	719,632	0	For
State Street	701,513	6,939	For
DE Shaw	673,382	0	For
Charles Schwab	620,561	0	For
ACADIAN ASSET MANAGEMENT LLC	558,077	0	For
Two Sigma	454,831	0	For
SEI	398,606	0	For
Janus Detroit Street Trust	350,637	0	For
Dimensional	310,251	0	For
Pacer Funds Trust	292,586	0	For
Invesco	253,928	0	For
683 Capital Management, LLC	250,000	0	For
MACKENZIE FINANCIAL CORP	248,682	0	For
Northern Trust	242,190	1,556	For
American Century	235,804	0	For
Delaware/Macquarie	208,783	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	208,783	0	For

Showing the 25 largest of 213 asset managers. See all 213 in the interactive database.

2. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Dean J. Mitchell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 42,557,257AGAINST: 297,316

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Dean J. Mitchell”): 42,557,257 for, 297,316 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 83% for, 0.6% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (8,427,589 for, 7,544 against).

FOR 99.7%

FOR: 8,427,589 (99.8%)AGAINST: 7,544 (0.1%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,161,406	3,444	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

3. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Deepika R. Pakianathan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 41,936,019AGAINST: 918,543

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 41,936,019 for, 918,543 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 81% for, 2% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 97% of the shares they voted on this item FOR (8,186,927 for, 248,206 against).

FOR 97%

FOR: 8,186,927 (96.9%)AGAINST: 248,206 (2.9%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,161,404	3,446	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	0	213,560	Against
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	24,325	26,000	Against
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

4. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Donal O'Connor

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 42,535,463AGAINST: 319,110

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 42,535,463 for, 319,110 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 83% for, 0.7% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (8,429,795 for, 5,337 against).

FOR 99.8%

FOR: 8,429,795 (99.8%)AGAINST: 5,337 (0.1%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,159,728	5,121	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

5. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Laurie Smaldone Alsup

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 42,725,649AGAINST: 124,187

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Laurie Smaldone Alsup”): 42,725,649 for, 124,187 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 83% for, 0.3% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (8,428,399 for, 6,734 against).

FOR 99.7%

FOR: 8,428,399 (99.8%)AGAINST: 6,734 (0.1%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,161,406	3,444	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

6. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Rick E Winningham

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 42,474,538AGAINST: 377,274

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 42,474,538 for, 377,274 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 82% for, 0.8% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (8,431,473 for, 3,660 against).

FOR 99.8%

FOR: 8,431,473 (99.8%)AGAINST: 3,660 (0.0%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,161,406	3,444	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

7. Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Susannah Gray

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 42,231,530AGAINST: 618,306

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 42,231,530 for, 618,306 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 51,515,000 outstanding shares: 82% for, 1% against (83% of the company cast a for/against vote).

The 67 asset managers below cast 98% of the shares they voted on this item FOR (8,224,672 for, 210,461 against).

FOR 97%

FOR: 8,224,672 (97.4%)AGAINST: 210,461 (2.5%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,163,172	1,678	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	0	208,783	Against
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

8. Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.7%

The 66 asset managers below cast 99.9% of the shares they voted on this item FOR (8,396,371 for, 6,401 against).

FOR: 8,396,371 (99.8%)AGAINST: 6,401 (0.1%)ABSTAIN: 11,536 (0.1%)

Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public acco” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,164,849	1	For
BlackRock	2,060,691	0	For
Fidelity	972,682	0	For
Janus Detroit Street Trust	350,637	0	For
Charles Schwab	309,563	0	For
Pacer Funds Trust	292,586	0	For
Invesco	237,758	0	For
Dimensional	231,199	0	For
State Street	213,560	0	For
Delaware/Macquarie	208,783	0	For
SEI	198,532	0	For
American Century	117,902	0	For
Equitable	112,903	0	For
TIAA	88,351	0	For
Goldman Sachs	66,103	0	For
QUANTITATIVE MASTER SERIES LLC	61,547	0	For
EA Series Trust	55,127	0	For
Principal Exchange-Traded Funds	50,440	0	For
Lincoln Financial	50,325	0	For
Legg Mason	47,355	0	For
Global X	42,704	0	For
MASTER INVESTMENT PORTFOLIO	42,704	0	For
ALPS ETF Trust	41,256	0	For
Prudential/PGIM	34,180	0	For
Northern Trust	33,616	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

9. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (34,798 for, 0 against).

FOR: 34,798 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Theravance Biopharma, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
CLEARWATER INVESTMENT TRUST	26,325	0	0	0	For
FORUM FUNDS II	8,473	0	0	0	For

Largest Theravance Biopharma, Inc. shareholders voting in 2025-2026

Ranked by the number of Theravance Biopharma, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 51,515,000 shares outstanding at the time of that meeting.

Top Theravance Biopharma, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Madison Avenue Partners, LP	17.36%
2	Newtyn Management, LLC	7.84%
3	BlackRock	7.10%
4	Irenic Capital Management LP	4.98%
5	Vanguard	4.81%
6	Fidelity	2.13%
7	GEODE CAPITAL MANAGEMENT, LLC	1.87%
8	Weiss Asset Management LP	1.49%
9	Janus Henderson	1.40%
10	State Street	1.38%

Reported Theravance Biopharma, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Theravance Biopharma, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Madison Avenue Partners, LP	18.46%	DEF14A
Madison Avenue International LP	17.88%	13G
Weiss Asset Management LP	14.48%	DEF14A
BlackRock	8.34%	13F
Newtyn Management, LLC	6.67%	13G
Irenic Capital Management LP	5.36%	DEF14A
Vanguard Group	4.60%	13F
Rick E Winningham	3.91%	DEF14A
State Street	2.52%	13F
Two Sigma	2.44%	13F

Percentages above are of 51,515,000 shares outstanding, as reported by Theravance Biopharma, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Theravance Biopharma, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Theravance Biopharma, Inc.'s shareholder meeting held 2026-06-12, in the 2025-2026 proxy season, 214 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,853 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approve the non-binding advisory resolution regarding the compensation of our named executive… — FOR was 99.4% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Theravance Biopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.

Theravance Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).